Anna holds a Bachelor’s degree in Biochemistry from the University of Barcelona and a Master’s degree in Human Genetics from the Autonomous University of Barcelona. During her studies, she completed internships in the Human Genetics Department at the University of Barcelona and the Molecular Genetics Department at Hospital Clinic of Barcelona.
After her academic journey, Anna joined Eli Lilly as a Medical Writer within the Epidemiology of Mental Disorders group at the Sant Joan de Déu Research Institute, where she gained her first experience in the pharmaceutical industry. Feeling prepared for further academic challenges, she pursued a PhD in Epidemiology within the same research group, focusing on the biological and psychological impacts of COVID-19 on individuals with pre-existing mental disorders. As part of her thesis work, Anna undertook a research stay at QIMR Berghofer in Brisbane, Australia, where she gained valuable experience in genetic epidemiology and broadened her scientific perspective through international collaboration.
Throughout her research career, Anna authored 16 publications, including 7 as first author, all featured in high-impact journals. Additionally, she presented her findings at four international conferences in neurosciences.
During her thesis, Anna also coordinated a clinical trial focused on improving the mental health of healthcare workers within the European project RESPOND. She found it deeply fulfilling to witness the positive impact of her work on the population. This experience motivated Anna to join the Angels Initiative, where she aims to make a meaningful difference in the lives of stroke patients.